foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Carmell Therapeutics advances plasma-based product...

Key learnings: Carmell™ Therapeutics closed its Series B round in June 2017...

Read More

Investor perspective: Sander Slootweg

Looking back at the past year, 2017 has proven to be a pretty successful ye...

Read More

Life sciences IPOs: Five things to consider

After spending all day on Wednesday 7 February at Biotech & Money’s IPO wor...

Read More

Desperately seeking alpha: the quest for value

"VC investor seeking long-term relationship. WLTM small cap, early-stage, o...

Read More

Leveraging larger capital pools in Europe

On 5 February 2018, the 4th annual Biotech and Money/Medtech and Money Worl...

Read More

The growth finance landscape in biotech 

The state of the market While the European venture capital market has faced...

Read More

INFOGRAPHIC: 2018 INVESTOR PERCEPTION SURVEY HIGHL...

This infographic presents key findings from the 2nd Biotech and Money Inves...

Read More

CRISPR in Europe: patent protection and the import...

CRISPR, the revolutionary gene-editing technology, presents huge opportunit...

Read More

Read the Biotech and Money Investor Perception Sur...

The Investor Perception Survey 2018 is now available to download. The repor...

Read More

Medius Deal Watch January 2018

One key question for 2018 is whether the recent US tax changes will have an...

Read More

STORM Therapeutics leads the way in RNA epigenetic...

Key learnings: STORM Therapeutics is developing small molecule inhibitors o...

Read More

Interview with Inmedix’s Andrew J. Holman

Andrew J. Holman, Co-Founder and Chief Executive Officer at Inmedix, talks ...

Read More

Add Your Response